Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

138 THE PREMENSTRUAL SYNDROMES
8. Wood SH, Mortola JF, Chan YF, Moossazadeh F, Yen SS.
Treatment of premenstrual syndrome with fluoxetine: a doubleblind,
placebo-controlled, crossover study. Obstet Gynecol 1992;
80:339–44.
9. Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment
of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual
Dysphoria Collaborative Study Group. N Engl J Med 1995;
332:1529–34.
10. Su TP, Schmidt PJ, Danaceau MA et al. Fluoxetine in the treatment
of premenstrual dysphoria. Neuropsychopharmacology 1997;
16:346–56.
11. Pearlstein T, Stone AB, Lund SA et al. Comparison of fluoxetine,
bupropion, and placebo in the treatment of premenstrual dysphoric
disorder. J Clin Psychopharmacol 1997; 17:261–6.
12. Ozeren S, Corrakci A, Yucesoy I, Mercan R, Erhan G. Fluoxetine
in the treatment of premenstrual syndrome. Eur J Obstet Gynecol
Reprod Biol 1997; 73:167–70.
13. Diegoli MS, da Fonseca AM, Diegoli CA, Pinotti JA. A doubleblind
trial of four medications to treat severe premenstrual syndrome.
Int J Gynaecol Obstet 1998; 62:63–7.
14. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus
castus extract in the treatment of premenstrual dysphoric disorder.
Hum Psychopharmacol 2003; 18:191–5.
15. Veeninga AT, Westenberg GM, Weusten JT. Fluvoxamine in the
treatment of menstrually related mood disorders. Psychopharmacology
1990; 102:414–16.
16. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin
reuptake inhibitor paroxetine is superior to the noradrenaline
reuptake inhibitor maprotiline in the treatment of premenstrual
syndrome. Neuropsychopharmacology 1995; 12:167–76.
17. Cohen LS, Soares CN, Yonkers KA et al. Paroxetine controlled
release for premenstrual dysphoric disorder: a double-blind,
placebo-controlled trial. Psychosom Med 2004; 66:707–13.
18. Pearlstein TB, Bellew KM, Endicott J, Steiner M. Paroxetine controlled
release for premenstrual dysphoric disorder: remission
analysis following a randomized, double-blind, placebo-controlled
trial. Prim Care Companion J Clin Psychiatry 2005; 7:53–60.
19. Yonkers KA, Halbreich U, Freeman E et al. Symptomatic
improvement of premenstrual dysphoric disorder with sertraline
treatment. JAMA 1997; 278:983–8.
20. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential
response to antidepressants in women with premenstrual syndrome/
premenstrual dysphoric disorder. A randomized controlled trial.
Arch Gen Psychiatry 1999; 56:932–9.
21. Freeman EW, Rickels K, Yonkers KA et al. Venlafaxine in the
treatment of premenstrual dysphoric disorder. Obstet Gynecol
2001; 98:737–44.
22. Hsiao M-C, Liu C-Y. Effective open-label treatment of premenstrual
dysphoric disorder with venlafaxine. Psychiatry Clin Neurosci
2003; 57:317–21.
23. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered
during the luteal phase reduces the symptoms of premenstrual
syndrome: a placebo-controlled trial. Neuropsychopharmacology
1993; 9:133–45.
24. Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. A
preliminary study of luteal phase versus symptom-onset dosing
with escitalopram for premenstrual dysphoric disorder. J Clin
Psychiatry 2005; 66:769–73.
25. Kodesh A, Katz S, Lerner AG, Finkel B, Sigal M. Intermittent,
luteal phase nefazodone treatment of premenstrual dysphoric
disorder. J Psychopharmacol 2001; 15:58–60.
26. Yonkers KA, Holthausen GA, Poschman K, Howell HB.
Symptom-onset treatment for women with premenstrual dysphoric
disorder. J Clin Psychopharmacol 2006; 26:198–202.
27. Miner C, Brown E, McCray S, Gonzales J, Wohlreich M. Weekly
luteal-phase dosing with enteric-coated fluoxetine 90 mg in
premenstrual dysphoric disorder: a randomized, double-blind,
placebo-controlled clinical trial. Clin Ther 2002; 24:417–33.
28. Cohen LS, Miner C, Brown EW et al. Premenstrual daily fluoxetine
for premenstrual dysphoric disorder: a placebo-controlled, clinical
trial using computerized diaries. Obstet Gynecol 2002; 100:435–44.
29. Landen M, Eriksson O, Sundblad C et al. Compounds with affinity
for serotonergic receptors in the treatment of premenstrual
dysphoria: a comparison of buspirone, nefazodone and placebo.
Psychopharmacology (Berl) 2001; 155:292–8.
30. Steiner M, Ravindran A, LeMelledo JM et al. Luteal-phase
administration of paroxetine for the treatment of premenstrual
dysphoric disorder: a randomized, double-blind, placebo controlled
trial in Canadian women. Can J Psychiatry 2006: (in press).
31. Steiner M, Hirschberg AL, Bergeron R et al. Luteal phase dosing
with paroxetine controlled release (CR) in the treatment of premenstrual
dysphoric disorder. Am J Obstet Gynecol 2005; 193:
352–60.
32. Halbreich U, Smoller JW. Intermittent luteal phase sertraline
treatment of dysphoric premenstrual syndrome. J Clin Psychiatry
1997; 58:399–402.
33. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of
premenstrual dysphoric disorder with sertraline during the luteal
phase: a randomized, double-blind, placebo-controlled crossover
trial. J Clin Psychiatry 1998; 59:76–80.
34. Jermain DM, Preece CK, Sykes RL, Kuehi TJ, Sulak PJ. Luteal
phase sertraline treatment for premenstrual dysphoric disorder.
Results of a double-blind, placebo-controlled, crossover study.
Arch Fam Med 1999; 8:328–32.
35. Halbreich U, Bergeron R, Yonkers KA et al. Efficacy of intermittent,
luteal phase sertraline treatment of premenstrual dysphoric
disorder. Obstet Gynecol 2002; 100:1219–29.
36. Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA.
Low-dose sertraline in the treatment of moderate-to-severe premenstrual
syndrome: efficacy of 3 dosing strategies. J Clin
Psychiatry 2006; 67:1624–32.
37. Steinberg S, Annable L, Young SN, Liyanage N. A placebocontrolled
clinical trial of L-tryptophan in premenstrual dysphoria.
Biol Psychiatry 1999; 45:313–20.
38. Cohen LS, Soares CN, Lyster A et al. Efficacy and tolerability of
premenstrual use of venlafaxine (flexible dose) in the treatment of
premenstrual dysphoric disorder. J Clin Psychopharmacol 2004;
24:540–3.
39. Wikander I, Sundblad C, Andersch B et al. Citalopram in premenstrual
dysphoria: is intermittent treatment during luteal phases
more effective than continuous medication throughout the menstrual
cycle? J Clin Psychopharmacol 1998; 18:390–8.
40. Freeman EW, Rickels K, Arredondo F et al. Full- or half-cycle
treatment of severe premenstrual syndrome with a serotonergic
antidepressant. J Clin Psychopharmacol 1999; 19:3–8.
41. Freeman EW, Jabara S, Sondheimer SJ, Auletto R. Citalopram in
PMS patients with prior SSRI treatment failure: a preliminary
study. J Womens Health Gend Based Med 2002; 11:459–64.
42. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S.
Continuous or intermittent dosing with sertraline for patients with
severe premenstrual syndrome or premenstrual dysphoric disorder.
Am J Psychiatry 2004; 161:343–51.
43. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine
dosing in the treatment of women with premenstrual dysphoria.
Psychopharmacol Bull 1997; 33:771–4.
44. Landen M, Nissbrandt H, Allgulander C et al. Placebo-controlled
trial comparing intermittent and continuous paroxetine in premenstrual
dysphoric disorder. Neuropsychopharmacology 2007;
32:153–61.
45. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual
dysphoric disorder: the emerging gold standard? Drugs
2002; 62:1869–85.